Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis.

P450 oxidoreductase (POR) is the obligatory flavoprotein intermediate that transfers electrons from reduced nicotinamide adenine dinucleotide phosphate (NADPH) to all microsomal cytochrome P450 enzymes. Although mouse Por gene ablation causes embryonic lethality, POR missense mutations cause disordered steroidogenesis, ambiguous genitalia, and Antley-Bixler syndrome (ABS), which has also been attributed to fibroblast growth factor receptor 2 (FGFR2) mutations. We sequenced the POR gene and FGFR2 exons 8 and 10 in 32 individuals with ABS and/or hormonal findings that suggested POR deficiency. POR and FGFR2 mutations segregated completely. Fifteen patients carried POR mutations on both alleles, 4 carried mutations on only one allele, 10 carried FGFR2 or FGFR3 mutations, and 3 patients carried no mutations. The 34 affected POR alleles included 10 with A287P (all from whites) and 7 with R457H (four Japanese, one African, two whites); 17 of the 34 alleles carried 16 "private" mutations, including 9 missense and 7 frameshift mutations. These 11 missense mutations, plus 10 others found in databases or reported elsewhere, were recreated by site-directed mutagenesis and were assessed by four assays: reduction of cytochrome c, oxidation of NADPH, support of 17alpha-hydroxylase activity, and support of 17,20 lyase using human P450c17. Assays that were based on cytochrome c, which is not a physiologic substrate for POR, correlated poorly with clinical phenotype, but assays that were based on POR's support of catalysis by P450c17--the enzyme most closely associated with the hormonal phenotype--provided an excellent genotype/phenotype correlation. Our large survey of patients with ABS shows that individuals with an ABS-like phenotype and normal steroidogenesis have FGFR mutations, whereas those with ambiguous genitalia and disordered steroidogenesis should be recognized as having a distinct new disease: POR deficiency.

[1]  D. Chitayat,et al.  FGFR2 mutation associated with clinical manifestations consistent with Antley-Bixler syndrome. , 1998, American journal of medical genetics.

[2]  C. Kasper,et al.  Association of Multiple Developmental Defects and Embryonic Lethality with Loss of Microsomal NADPH-Cytochrome P450 Oxidoreductase* , 2002, The Journal of Biological Chemistry.

[3]  J. Thompson,et al.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.

[4]  K. Inouye,et al.  Electrostatic interaction between cytochrome P450 and NADPH-P450 reductase: comparison of mixed and fused systems consisting of rat cytochrome P450 1A1 and yeast NADPH-P450 reductase. , 1999, Biochemical and biophysical research communications.

[5]  J. Abraham,et al.  Fluconazole-induced congenital anomalies in three infants. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[7]  T. Omura,et al.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. , 1964, The Journal of biological chemistry.

[8]  Nigel S. Scrutton,et al.  Redesign of the coenzyme specificity of a dehydrogenase by protein engineering , 1990, Nature.

[9]  W. Miller.  Congenital adrenal hyperplasia. , 1987, The New England journal of medicine.

[10]  Israel Hanukoglu,et al.  cDNA sequence of adrenodoxin reductase. Identification of NADP-binding sites in oxidoreductases. , 1989, European journal of biochemistry.

[11]  T. E. Wilson,et al.  Structural analysis of the FMN binding domain of NADPH-cytochrome P-450 oxidoreductase by site-directed mutagenesis. , 1989, The Journal of biological chemistry.

[12]  M. Shet,et al.  Construction of plasmids and expression in Escherichia coli of enzymatically active fusion proteins containing the heme-domain of a P450 linked to NADPH-P450 reductase. , 1996, Methods in enzymology.

[13]  C. Wolf,et al.  Inactivation of the Hepatic Cytochrome P450 System by Conditional Deletion of Hepatic Cytochrome P450 Reductase* , 2003, The Journal of Biological Chemistry.

[14]  N. Guex,et al.  SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling , 1997, Electrophoresis.

[15]  D. Bixler,et al.  Trapezoidocephaly, midfacial hypoplasia and cartilage abnormalities with multiple synostoses and skeletal fractures. , 1975, Birth defects original article series.

[16]  C. Kasper,et al.  Role of Acidic Residues in the Interaction of NADPH-Cytochrome P450 Oxidoreductase with Cytochrome P450 and Cytochrome c(*) , 1995, The Journal of Biological Chemistry.

[17]  E. Zackai,et al.  Mutations in FGFR1 and FGFR2 cause familial and sporadic Pfeiffer syndrome. , 1995, Human molecular genetics.

[18]  W. Miller,et al.  Molecular modeling of human P450c17 (17alpha-hydroxylase/17,20-lyase): insights into reaction mechanisms and effects of mutations. , 1999, Molecular endocrinology.

[19]  W. Reardon,et al.  A common mutation in the fibroblast growth factor receptor 1 gene in Pfeiffer syndrome , 1994, Nature Genetics.

[20]  D. Bartley,et al.  Multiple malformation syndrome following fluconazole use in pregnancy: report of an additional patient. , 1997, American journal of medical genetics.

[21]  N. Green,et al.  The syndrome of multisynostotic osteodysgenesis with long-bone fractures. , 1980, American journal of medical genetics.

[22]  B. Masters,et al.  Chimeric Enzymes of Cytochrome P450 Oxidoreductase and Neuronal Nitric-oxide Synthase Reductase Domain Reveal Structural and Functional Differences* , 2003, Journal of Biological Chemistry.

[23]  J. Sack,et al.  Ambiguous genitalia due to partial activity of cytochromes P450c17 and P450c21 , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[24]  W. Kress,et al.  An unusual FGFR1 mutation (fibroblast growth factor receptor 1 mutation) in a girl with non-syndromic trigonocephaly , 2001, Cytogenetic and Genome Research.

[25]  Sue Malcolm,et al.  Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome , 1994, Nature Genetics.

[26]  R. Auchus.  The backdoor pathway to dihydrotestosterone , 2004, Trends in Endocrinology & Metabolism.

[27]  W. Miller,et al.  Thiazolidinediones but Not Metformin Directly Inhibit the Steroidogenic Enzymes P450c17 and 3β-Hydroxysteroid Dehydrogenase* , 2001, The Journal of Biological Chemistry.

[28]  W. Miller,et al.  P450 oxidoreductase deficiency: a new disorder of steroidogenesis with multiple clinical manifestations , 2004, Trends in Endocrinology & Metabolism.

[29]  E. C. Slater,et al.  The extinction coefficient of cytochrome c. , 1962, Biochimica et biophysica acta.

[30]  G. Herman.  Disorders of cholesterol biosynthesis: prototypic metabolic malformation syndromes. , 2003, Human molecular genetics.

[31]  Philip A Beachy,et al.  Novel lipid modifications of secreted protein signals. , 2004, Annual review of biochemistry.

[32]  H. Cui,et al.  Liver-specific Deletion of the NADPH-Cytochrome P450 Reductase Gene , 2003, Journal of Biological Chemistry.

[33]  T. Ogata,et al.  Cytochrome P450 oxidoreductase gene mutations and Antley-Bixler syndrome with abnormal genitalia and/or impaired steroidogenesis: molecular and clinical studies in 10 patients. , 2005, The Journal of clinical endocrinology and metabolism.

[34]  W. Miller,et al.  Protein Phosphatase 2A and Phosphoprotein SET Regulate Androgen Production by P450c17* , 2003, The Journal of Biological Chemistry.

[35]  E. Jabs,et al.  Ocular anterior chamber dysgenesis in craniosynostosis syndromes with a fibroblast growth factor receptor 2 mutation. , 1999, American journal of medical genetics.

[36]  D. Sem,et al.  Mechanistic Studies on the Reductive Half-reaction of NADPH-Cytochrome P450 Oxidoreductase* , 1999, The Journal of Biological Chemistry.

[37]  D. Nelson,et al.  Cytochrome P-450: cytochrome P-450 reductase interactions. , 1989, Drug metabolism reviews.

[38]  D. Sillence,et al.  Evidence for digenic inheritance in some cases of Antley-Bixler syndrome? , 2000, Journal of medical genetics.

[39]  M. Eccles,et al.  Jackson-Weiss and Crouzon syndromes are allelic with mutations in fibroblast growth factor receptor 2 , 1994, Nature Genetics.

[40]  J Deisenhofer,et al.  Structure and function of cytochromes P450: a comparative analysis of three crystal structures. , 1995, Structure.

[41]  P. White,et al.  Congenital Adrenal Hyperplasia , 1964, The Lancet.

[42]  J. Masel,et al.  A new multiple malformation syndrome of Müllerian dysgenesis and conductive hearing loss with facial hypoplasia, bilateral forearm deformity, brachydactyly, spinal stenosis and scoliosis , 1997, Clinical genetics.

[43]  T. Iyanagi,et al.  Structural analysis of NADPH-cytochrome P-450 reductase from porcine hepatic microsomes. Sequences of proteolytic fragments, cysteine-containing peptides, and a NADPH-protected cysteine peptide. , 1984, The Journal of biological chemistry.

[44]  W. Reardon,et al.  Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome , 1995, Nature Genetics.

[45]  K. Yanagibashi,et al.  Role of electron transport in the regulation of the lyase activity of C21 side-chain cleavage P-450 from porcine adrenal and testicular microsomes. , 1986, The Journal of biological chemistry.

[46]  W. Miller,et al.  Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[47]  W. Miller,et al.  Clinical review 54: Genetics, diagnosis, and management of 21-hydroxylase deficiency. , 1994, The Journal of clinical endocrinology and metabolism.

[48]  P. Karplus,et al.  Atomic structure of ferredoxin-NADP+ reductase: prototype for a structurally novel flavoenzyme family. , 1991, Science.

[49]  S. Warmann,et al.  Congenital adrenal hyperplasia associated with maternal pregnancy luteoma and the Antley-Bixler syndrome. , 2000, Journal of pediatric surgery.

[50]  H. Strobel,et al.  Identification and characterization of an NADPH-cytochrome P450 reductase derived peptide involved in binding to cytochrome P450. , 1991, Archives of biochemistry and biophysics.

[51]  A. Sali,et al.  Modeling of loops in protein structures , 2000, Protein science : a publication of the Protein Society.

[52]  D. Pompon,et al.  Genetically engineered yeast cells and their applications. , 1995, Toxicology letters.

[53]  B. Masters,et al.  Three-dimensional structure of NADPH-cytochrome P450 reductase: prototype for FMN- and FAD-containing enzymes. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[54]  W. Miller,et al.  P450c17 mutations R347H and R358Q selectively disrupt 17,20-lyase activity by disrupting interactions with P450 oxidoreductase and cytochrome b5. , 1999, Molecular endocrinology.

[55]  C. W. Fisher,et al.  The interaction of NADPH-P450 reductase with P450: an electrochemical study of the role of the flavin mononucleotide-binding domain. , 1996, Archives of biochemistry and biophysics.

[56]  E. Jabs,et al.  FGFR2 exon IIIa and IIIc mutations in Crouzon, Jackson-Weiss, and Pfeiffer syndromes: evidence for missense changes, insertions, and a deletion due to alternative RNA splicing. , 1996, American journal of human genetics.

[57]  C. Kasper,et al.  Differential Contributions of NADPH-Cytochrome P450 Oxidoreductase FAD Binding Site Residues to Flavin Binding and Catalysis* , 2000, The Journal of Biological Chemistry.

[58]  F Peter Guengerich,et al.  Cytochrome P450: What Have We Learned and What Are the Future Issues? , 2004, Drug metabolism reviews.

[59]  P. Swiatek,et al.  Transgenic Mice with a Hypomorphic NADPH-Cytochrome P450 Reductase Gene: Effects on Development, Reproduction, and Microsomal Cytochrome P450 , 2005, Journal of Pharmacology and Experimental Therapeutics.

[60]  S. Black,et al.  Steroid 17 alpha-hydroxylase and 17,20-lyase activities of P450c17: contributions of serine106 and P450 reductase. , 1993, Endocrinology.

[61]  K. Jones,et al.  Missense mutation serine106----proline causes 17 alpha-hydroxylase deficiency. , 1991, The Journal of biological chemistry.

[62]  M. Butler,et al.  Antley‐Bixler syndrome: report of a patient and review of literature , 1994, Clinical genetics.

[63]  K. Tachibana,et al.  Compound heterozygous mutations of cytochrome P450 oxidoreductase gene (POR) in two patients with Antley–Bixler syndrome , 2004, American journal of medical genetics. Part A.

[64]  C. Kasper,et al.  NADPH-cytochrome P-450 oxidoreductase. The role of cysteine 566 in catalysis and cofactor binding. , 1991, The Journal of biological chemistry.

[65]  W. Reardon,et al.  Spectrum of Craniosynostosis Phenotypes Associated with Novel Mutations at the Fibroblast Growth Factor Receptor 2 Locus , 1996, European journal of human genetics : EJHG.

[66]  Athel Cornish-Bowden,et al.  Analysis of enzyme kinetic data , 1995 .

[67]  C. Tickle,et al.  Identification of Novel Roles of the Cytochrome P450 System in Early Embryogenesis: Effects on Vasculogenesis and Retinoic Acid Homeostasis , 2003, Molecular and Cellular Biology.

[68]  L. Waskell,et al.  High-level expression in Escherichia coli and purification of the membrane-bound form of cytochrome b(5). , 2000, Protein expression and purification.

[69]  W. Miller,et al.  The genetic and functional basis of isolated 17,20–lyase deficiency , 1997, Nature Genetics.

[70]  B. Delobel,et al.  Antley-Bixler syndrome: case report and review of the literature. , 1995, Genetic counseling.

[71]  Rivka L. Glaser,et al.  Abnormal sterol metabolism in a patient with Antley-Bixler syndrome and ambiguous genitalia. , 2002, American journal of medical genetics.

[72]  P. Ortiz de Montellano,et al.  Glu-320 and Asp-323 are determinants of the CYP4A1 hydroxylation regiospecificity and resistance to inactivation by 1-aminobenzotriazole. , 1998, Biochemistry.

[73]  E. Zackai,et al.  Phenotype of the fibroblast growth factor receptor 2 Ser351Cys mutation: Pfeiffer syndrome type III. , 1998, American journal of medical genetics.

[74]  Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase , 1991 .

[75]  T. Lee,et al.  Structural and functional analysis of NADPH-cytochrome P-450 reductase from human liver: complete sequence of human enzyme and NADPH-binding sites. , 1989, Biochemistry.

[76]  E. Jabs,et al.  Novel FGFR2 mutations in Crouzon and Jackson-Weiss syndromes show allelic heterogeneity and phenotypic variability. , 1995, Human molecular genetics.

[77]  H. Losken,et al.  Crouzon syndrome: mutations in two spliceoforms of FGFR2 and a common point mutation shared with Jackson-Weiss syndrome. , 1995, Human molecular genetics.

[78]  E. Jabs,et al.  Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome , 2004, Nature Genetics.

[79]  M. Lakomek,et al.  Features of Antley-Bixler syndrome in an infant born to a mother with pregnancy luteoma , 2000, European Journal of Pediatrics.

[80]  J. Kelleher,et al.  Antley-Bixler syndrome with radioulnar synostosis , 2004, Pediatric Radiology.

[81]  M. J. Coon,et al.  Resolution of the cytochrome P-450-containing omega-hydroxylation system of liver microsomes into three components. , 1969, The Journal of biological chemistry.

[82]  R. E. Peterson,et al.  Male pseudohermaphroditism due to multiple defects in steroid-biosynthetic microsomal mixed-function oxidases. A new variant of congenital adrenal hyperplasia. , 1985, The New England journal of medicine.

[83]  C. Shackleton,et al.  Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study , 2004, The Lancet.

[84]  Gillian M Morriss-Kay,et al.  A gain-of-function mutation of Fgfr2c demonstrates the roles of this receptor variant in osteogenesis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[85]  J. Walker,et al.  Over-production of proteins in Escherichia coli: mutant hosts that allow synthesis of some membrane proteins and globular proteins at high levels. , 1996, Journal of molecular biology.

[86]  K. Bloch,et al.  Solubilization and partial characterization of rat liver squalene epoxidase. , 1975, The Journal of biological chemistry.

[87]  J. Peterson,et al.  Association of cytochromes P450 with their reductases: opposite sign of the electrostatic interactions in P450BM-3 as compared with the microsomal 2B4 system. , 2000, Biochemistry.

[88]  H. Strobel,et al.  Role of electrostatic interactions in the reaction of NADPH-cytochrome P-450 reductase with cytochromes P-450. , 1988, Archives of biochemistry and biophysics.

[89]  M. Bamshad,et al.  Fibroblast growth factor receptor 2 mutations in Beare–Stevenson cutis gyrata syndrome , 1996, Nature Genetics.

[90]  G. Heijne.  Analysis of the distribution of charged residues in the N‐terminal region of signal sequences: implications for protein export in prokaryotic and eukaryotic cells. , 1984, The EMBO journal.

[91]  P. Swiatek,et al.  Conditional knockout of the mouse NADPH‐cytochrome p450 reductase gene , 2003, Genesis.

[92]  L. Waskell,et al.  High-Level Expression in Escherichia coli and Purification of the Membrane-Bound Form of Cytochrome b5 , 2000 .

[93]  E. Jabs,et al.  Analysis of phenotypic features and FGFR2 mutations in Apert syndrome. , 1995, American journal of human genetics.

[94]  W. Miller,et al.  Cytochrome b 5 Augments the 17,20-Lyase Activity of Human P450c17 without Direct Electron Transfer* , 1998, The Journal of Biological Chemistry.